Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2408185 | Vaccine | 2007 | 10 Pages |
Abstract
We have constructed a replication competent, γ134.5-deleted herpes simplex virus type-1 (HSV-1) vector (J200) that expresses the gag gene from human immunodeficiency virus type-1, primary isolate 89.6 (HIV-189.6), as a candidate vaccine for HIV-1. J200 replicates in vitro, resulting in abundant Gag protein production and accumulation in the extracellular media. Immunization of Balb/c mice with a single intraperitoneal injection of J200 elicited strong Gag-specific CD8 responses, as measured by intracellular IFN-γ staining and flow cytometry analysis. Responses were highest between 6 weeks and 4 months, but persisted at 9 months post-immunization, the last time-point evaluated. These data highlight the potential utility of neuroattenuated, replication competent HSV-1 vectors for delivery of HIV-1 immunogens.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Scott D. Parker, Scott T. Rottinghaus, Allan J. Zajac, Ling Yue, Eric Hunter, Richard J. Whitley, Jacqueline N. Parker,